Camden National Bank increased its stake in Novartis AG (NYSE:NVS) by 1.1% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 74,420 shares of the company’s stock after acquiring an additional 809 shares during the quarter. Camden National Bank’s holdings in Novartis were worth $6,467,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently modified their holdings of NVS. Asset Dedication LLC grew its holdings in shares of Novartis by 98.7% in the 2nd quarter. Asset Dedication LLC now owns 304 shares of the company’s stock worth $27,000 after acquiring an additional 151 shares during the last quarter. Moneta Group Investment Advisors LLC grew its holdings in shares of Novartis by 795.8% in the 2nd quarter. Moneta Group Investment Advisors LLC now owns 2,750 shares of the company’s stock worth $27,000 after acquiring an additional 2,443 shares during the last quarter. Vigilant Capital Management LLC acquired a new position in shares of Novartis in the 2nd quarter worth $37,000. Anderson Fisher LLC acquired a new position in shares of Novartis in the 2nd quarter worth $39,000. Finally, Manchester Financial Inc. acquired a new position in shares of Novartis in the 2nd quarter worth $45,000. Institutional investors and hedge funds own 11.19% of the company’s stock.
Shares of NVS stock traded up $0.63 on Friday, reaching $86.56. 41,491 shares of the company’s stock traded hands, compared to its average volume of 1,838,232. Novartis AG has a 12-month low of $71.86 and a 12-month high of $95.00. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 0.94. The company has a market capitalization of $195.54 billion, a P/E ratio of 17.05, a price-to-earnings-growth ratio of 2.27 and a beta of 0.59. The business’s 50 day moving average price is $87.73 and its two-hundred day moving average price is $87.94.
NVS has been the topic of a number of recent research reports. Argus lifted their target price on Novartis to $105.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. They noted that the move was a valuation call. Jefferies Financial Group restated a “buy” rating on shares of Novartis in a report on Thursday, August 29th. Zacks Investment Research cut Novartis from a “buy” rating to a “hold” rating and set a $100.00 target price on the stock. in a report on Friday, July 19th. Kepler Capital Markets cut Novartis from a “buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Finally, ValuEngine cut Novartis from a “hold” rating to a “sell” rating in a report on Thursday, September 12th. Five equities research analysts have rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $93.29.
Novartis Company Profile
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Featured Story: Which market index is the best?
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.